Altimmune, Inc.
ALTHealthcare|Biotechnology|US
$2.08
+0.11 (+5.58%)
DCF Value
$0.08
Tangible Book / Share
$2.56
Cash / Share
$1.76
Clinical Trials (20)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07795164 Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | P3 | Recruiting | 1,800 | RCT, Double-blind | Pemvidutide |
| NCT07009860 RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Alcohol-associated Liver Disease | P2 | Active | 121 | RCT, Double-blind | Pemvidutide |
| NCT03163342 Immune Response Following Seasonal Influenza Vaccination | Influenza | P4 | Completed | 20 | Open-label | Licensed seasonal influenza vaccine |
| NCT06987513 RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight | Alcohol Use Disorder (AUD) | P2 | Completed | 100 | RCT, Double-blind | Pemvidutide |
| NCT05989711 IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) | Non-Alcoholic Steatohepatitis (NASH) | P2 | Completed | 212 | RCT, Double-blind | Pemvidutide, Placebo |
| NCT03232567 Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX | Influenza | P2 | Completed | 60 | RCT, Double-blind | NasoVAX |
| NCT04684914 HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) | Hepatitis B, Chronic | P2 | Terminated | 87 | RCT, Double-blind | HepTcell, Placebo |
| NCT05295875 Efficacy and Safety of ALT-801 in the Treatment of Obesity | Obesity/Overweight | P2 | Completed | 391 | RCT, Double-blind | ALT-801 |
| NCT04442230 NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) | Coronavirus Infection | P2 | Terminated | 48 | RCT, Double-blind | NasoVAX |
| NCT04679909 Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) | Healthy Volunteers | P1 | Completed | 92 | RCT, Double-blind | AdCOVID |
| NCT04415749 NasoShield in Healthy Adults to Study Safety and Immunogenicity | Healthy Volunteers | P1 | Completed | 43 | RCT, Double-blind | NasoShield |
| NCT00755703 Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine. | Influenza A Subtype H5N1 Infection | P1 | Completed | 48 | RCT, Double-blind | Pandemic Influenza Vaccine, Placebo |
| NCT03352466 NasoShield Study of Safety and Immunogenicity | Healthy Volunteers | P1 | Completed | 145 | RCT, Double-blind | NasoShield, BioThrax |
| NCT05006885 ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) | Non-Alcoholic Fatty Liver Disease | P1 | Completed | 95 | RCT, Double-blind | ALT-801 |
| NCT05134662 ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes | P1 | Completed | 55 | RCT, Double-blind | ALT-801 |
| NCT05292911 Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) | Non-Alcoholic Fatty Liver Disease | P1 | Completed | 64 | RCT, Double-blind | ALT-801 |
| NCT02496897 Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B | Hepatitis B | P1 | Completed | 61 | RCT, Double-blind | FP-02.2 Vaccine |
| NCT04561245 ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability | Obesity, Nonalcoholic Steatohepatitis | P1 | Completed | 100 | RCT, Double-blind | ALT-801 |
| NCT04972396 Pemvidutide (ALT-801) DDI Study in Healthy Volunteers | NASH - Nonalcoholic Steatohepatitis | P1 | Completed | 40 | RCT, Open-label | Pemvidutide, Metformin, Atorvastatin, Warfarin, Digoxin, Ethinylestradiol and Levonorgestrel |
| NCT03760549 Study of the Safety and Immunogenicity of NasoVAX Extension | Influenza | Completed | 8 | — | Subjects were administered NasoVAX high dose |